Pharmacorp Clinical Trials, Inc. | Charleston, SC

Research site

(Unclaimed)

Location

418 Folly Road Suite A, Charleston, South Carolina, United States of America

Site insights

Top conditions

Top treatments

Upadacitinib

ABT-494

Pregabalin

Tolterodine

BLU-5937

Vibegron

Canakinumab

naltrexone hydrochloride

EMBEDA

Ranolazine

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

5 of 24 total trials

A 24-Week Study of the Efficacy and Safety of BLU-5937 in Adults With Refractory Chronic Cough (CALM-2)

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling

Refractory Chronic Cough

Drug: Placebo

Drug: BLU-5937

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 (U-ENDURE)

A multicenter study to evaluate the efficacy and safety of maintenance and long-term treatment administration of upadacitinib, an orally administered...

Active, not recruiting

Crohn's Disease

Drug: Placebo for Upadacitinib

Drug: Upadacitinib

A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) (U-ACHIEVE)

This study is designed to evaluate the long-term safety and efficacy of Upadacitinib in participants with ulcerative colitis (UC) who have not respon...

Active, not recruiting

Ulcerative Colitis (UC)

Drug: Placebo

Drug: Upadacitinib (ABT-494)

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke (VESALIUS-CV)

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults wi...

Active, not recruiting

Coronary Heart Disease (CHD)

Drug: Evolocumab

Drug: Placebo

Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease (AMPLITUDE)

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants...

Enrolling

Proteinuric Kidney Disease

Drug: Placebo

Drug: VX-147